Related Experiment Video
Updated: Jun 21, 2025

06:14
Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
8.8K
Translocator protein and neurodegeneration: insights from Alzheimer's disease
Arpit Kumar Pradhan1,2, Rainer Rupprecht3, Gerhard Rammes1
1Klinik für Anaesthesiologie und Intensivmedizin der Technischen Universität München, Klinikum rechts der Isar, Munich, Germany (Pradhan AK, Rammes G).
Neural Regeneration Research
|July 11, 2024
Abstract
No abstract available in PubMed .
Related Concept Videos
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177

